Related Experiment Videos
Fibrinolysis and atherosclerosis
1King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
Insights
Impaired fibrinolysis is increasingly linked to coronary heart disease (CHD). Further research into molecular mechanisms and genotype-specific factors is crucial for developing targeted prevention strategies.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Thrombosis Research
Background:
- Growing evidence links impaired fibrinolytic function to coronary heart disease (CHD).
- Epidemiological, clinical, and molecular studies have reinforced this association.
- Established risk factors for atherosclerotic disease may influence fibrinolysis.
Purpose of the Study:
- To elucidate the molecular mechanisms connecting risk factors, impaired fibrinolysis, and CHD.
- To explore genotype-specific differences in susceptibility to metabolic disturbances affecting fibrinolysis.
- To prioritize basic research on fibrinolysis in atherosclerosis and thrombotic complications.
Main Methods:
- Review and synthesis of epidemiological, clinical, cell biological, and molecular biological studies.
- Analysis of established risk factors for atherosclerotic disease.
- Investigation into molecular mechanisms underlying fibrinolysis impairment.
Main Results:
- The association between impaired fibrinolysis and CHD is strongly supported by recent research.
- Understanding molecular mechanisms is key for developing targeted drugs.
- The role of epiphenomena and genotype-specific variations requires further investigation.
Conclusions:
- Modulating fibrinolytic function presents a promising avenue for CHD prevention.
- Further research is needed to disentangle complex molecular pathways.
- Prioritizing basic science research on fibrinolysis is essential for advancing cardiovascular health.
Abstract:
The link between impaired fibrinolytic function and CHD has been reinforced considerably in the past couple of years. This has been achieved by a combination of epidemiological, clinical, cell biological and molecular biological studies. The molecular mechanisms for the identified associations between more established risk factors for atherosclerotic disease and impaired fibrinolytic function now need to be disentangled to promote the design of specific drugs that may pave the way for intervention. The possibility that some of the observed relations are epiphenomena should also not be disregarded. The concept of genotype-specific differences in the susceptibility of the individual to common metabolic disturbances needs to be examined in greater detail. Basic research on the role of fibrinolysis in atherosclerosis and its thrombotic complications should be given high priority, because the modulation of fibrinolytic function is likely to become an important approach to prevention.